Sugi Predict

Sugi Predict / Compounds / SCHEMBL293386

SCHEMBL293386

SCHEMBL293386

CN(C)C(=O)N=NC(N)=O

nearest known ligand 0.72

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.72
▸ HSD17B10 Q99714 2/20 0.72
▸ TSHR P16473 2/20 0.72
▸ PMP22 Q01453 2/20 0.72
▸ NFKB1 P19838 1/20 0.72
▸ THPO P40225 1/20 0.72
▸ MAPT P10636 1/20 0.72
▸ APEX1 P27695 1/20 0.72
▸ CYP3A4 P08684 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ EHMT2 Q96KQ7 1/20 0.56
▸ EHMT1 Q9H9B1 1/20 0.56
▸ LMNA P02545 1/20 0.30
▸ ALOX15 P16050 1/20 0.30
▸ BLM P54132 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11800451 1.00 ALDH1A1 (0.72) ALDH1A1HSD17B10TSHRPMP22NFKB1
Diamide SCHEMBL103289 0.85 TSHR (1.00) ALDH1A1HSD17B10TSHRPMP22NFKB1
Diamide SCHEMBL13680778 0.85 TSHR (1.00) ALDH1A1HSD17B10TSHRPMP22NFKB1
Diamide SCHEMBL39340 0.85 TSHR (1.00) ALDH1A1HSD17B10TSHRPMP22NFKB1
Diamide SCHEMBL9621172 0.83 ALDH1A1 (0.72) ALDH1A1HSD17B10TSHRPMP22NFKB1
Diamide SCHEMBL1681704 0.82 TSHR (0.93) ALDH1A1HSD17B10TSHRPMP22NFKB1
Diamide SCHEMBL2036888 0.82 TSHR (0.93) ALDH1A1HSD17B10TSHRPMP22NFKB1
Diamide SCHEMBL1772314 0.82 TSHR (0.93) ALDH1A1HSD17B10TSHRPMP22NFKB1
Diamide SCHEMBL29975194 0.82 TSHR (0.93) ALDH1A1HSD17B10TSHRPMP22NFKB1
Diamide SCHEMBL8186446 0.82 TSHR (0.93) ALDH1A1HSD17B10TSHRPMP22NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240308991-A1 PROCESS FOR THE SYNTHESIS OF REACTIVE CARBOHYDRATES INCLUDING ANTIGEN PRECURSORS FOR CONJUGATION WITH A CARRIER MATERIAL KORANEX CAPITAL (CA) 2024-09-19 — — US claimed
US-10610576-B2 Precision glycoconjugates as therapeutic tools KORANEX CAPITAL (CA) 2020-04-07 — — US claimed
US-20190290746-A1 PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS KORANEX CAPITAL (CA) 2019-09-26 — — US claimed
EP-1032401-B1 METHOD FOR INHIBITING CYTOKINE PRODUCTION BY CELLS PREVISAN AG (CH) 2005-03-16 — — EP claimed
EP-0941098-B1 METHOD FOR INHIBITING DESOXYRIBONUCLEOTIDE TRIPHOSPHATE BIOSYNTHESIS PREVISAN AG (CH) 2003-05-14 — — EP claimed
US-6407081-B1 ADMINISTERING AZOBISFORMAMIDE OR AZOBISFORMAMIDINE DERIVATIVE TO INHIBIT INTERLEUKINS, INTERFERONS AND TUMOR NECROSIS FACTOR PREVISAN AG (CH) 2002-06-18 — — US claimed
US-6271218-B1 USING AN AZO COMPOUND PREVISAN AG (CH) 2001-08-07 — — US claimed
EP-1032401-A2 METHOD FOR INHIBITING CYTOKINE PRODUCTION BY CELLS Previsan AG (CH) 2000-09-06 — — EP claimed
EP-0941098-A1 METHOD FOR INHIBITING DESOXYRIBONUCLEOTIDE TRIPHOSPHATE BIOSYNTHESIS Previsan AG (CH) 1999-09-15 — — EP claimed
WO-1999027937-A2 METHOD FOR INHIBITING CYTOKINE PRODUCTION BY CELLS PREVISAN AG (CH) 1999-06-10 — — WO claimed
WO-1998010772-A1 METHOD FOR INHIBITING DESOXYRIBONUCLEOTIDE TRIPHOSPHATE BIOSYNTHESIS PREVISAN AG (CH) 1998-03-19 — — WO claimed
EP-4446336-A2 NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS Koranex Capital (CA) 2024-10-16 — — EP disclosed
US-20240308991-A1 PROCESS FOR THE SYNTHESIS OF REACTIVE CARBOHYDRATES INCLUDING ANTIGEN PRECURSORS FOR CONJUGATION WITH A CARRIER MATERIAL KORANEX CAPITAL (CA) 2024-09-19 — — US disclosed
US-20240216491-A1 NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS KORANEX CAPITAL (CA) 2024-07-04 — — US disclosed
US-11925680-B2 Neoglycoconjugates as vaccines and therapeutic tools KORANEX CAPITAL (CA) 2024-03-12 — — US disclosed
EP-0941098-A1 METHOD FOR INHIBITING DESOXYRIBONUCLEOTIDE TRIPHOSPHATE BIOSYNTHESIS Previsan AG (CH) 1999-09-15 — — EP disclosed
WO-1999027937-A2 METHOD FOR INHIBITING CYTOKINE PRODUCTION BY CELLS PREVISAN AG (CH) 1999-06-10 — — WO disclosed
WO-1998010772-A1 METHOD FOR INHIBITING DESOXYRIBONUCLEOTIDE TRIPHOSPHATE BIOSYNTHESIS PREVISAN AG (CH) 1998-03-19 — — WO disclosed
US-4104301-A BLOWING AGENTS ARMSTRONG CORK COMPANY (US) 1978-08-01 — — US disclosed
US-3940365-A PHENOLIC ANTIOXIDANT AND AN UREA OR AN OXALIC ACID DIAMIDE OR AN AZODICARBOXYLIC AMIDE HOECHST AKTIENGESELLSCHAFT (DT) 1976-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10610576-B2 Precision glycoconjugates as therapeutic tools STT3B, STT3A, SIGLEC7 ALDH1A1 1454/4885HSD17B10 1017/4885TSHR 1736/4885
US-20240216491-A1 NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS GNE, B3GNT2, KRTCAP2 ALDH1A1 4018/4885HSD17B10 2896/4885TSHR 1739/4885
US-20190290746-A1 PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS STT3B, STT3A, SIGLEC7 ALDH1A1 1454/4885HSD17B10 1017/4885TSHR 1736/4885
US-11925680-B2 Neoglycoconjugates as vaccines and therapeutic tools GNE, B3GNT2, KRTCAP2 ALDH1A1 4018/4885HSD17B10 2896/4885TSHR 1739/4885
US-20240308991-A1 PROCESS FOR THE SYNTHESIS OF REACTIVE CARBOHYDRATES INCLUDING ANTIGEN PRECURSORS FOR CONJUGATION WITH A CARRIER MATERIAL OSTC, CA11, OXGR1 ALDH1A1 3268/4885HSD17B10 4585/4885TSHR 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.